Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Amneal Pharmaceuticals, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

There has not been any material change in our assessment of market risk as set forth in Item 7A. Quantitative and Qualitative Disclosures About Market Risk, in our 2025 Annual Report on Form 10-K.